TARS (tarsusrx.com) Net earnings per share (EPS TTM)

tarsusrx.com (TARS) - corporate logo

The success of Tarsus Pharmaceuticals (TARS) depends on the commercial takeoff of Xdemvy and the control of marketing expenses during the drug's rollout to pharmacies. The rolling 12-month net income per share visualizes the operational trend, where -15.05 serves as the current metric level. The company's revenues are based on the sale of innovative drops to ophthalmology centers and patients, paid via insurance policies or personal funds.

TARS (Tarsus Corp) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/15/2026

Tarsus Pharma (TARS) - metric breakdowns and financial figures

- current quotes and average value forecast:
Price Chart Tarsus Pharma|TARS - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization Tarsus Pharmaceuticals Inc|TARS - Full Business Value
- business book valuation details:
Book Value per Share Tarsus Pharmaceuticals|TARS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio tarsusrx.com|TARS - Cumulative Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Tarsus Pharmaceuticals|TARS - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital tarsusrx.com|TARS - Company Total Debt Obligations|Debt to Book Capitalization Ratio Tarsus Pharmaceuticals, Inc.|TARS - Long-Term Debt|Company Short-Term Debt Tarsus Pharmaceuticals|Quick Liquidity tarsusrx.com
- net income and valuation multiples indicators:
TARS - Net Financial Result|Future Profit Tarsus Pharmaceuticals|TARS - Market Price to Net Income Ratio|Forward P/E Multiple Tarsus Pharmaceuticals Inc|TARS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tarsus Corp|TARS - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Tarsus Pharmaceuticals|TARS - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months tarsusrx.com|TARS - Earnings growth in current year|Net earnings per share growth forecast for next year Tarsus Pharmaceuticals
- revenue and sales proceeds data:
TARS - Company Gross Revenue|Company Future Sales Volume Tarsus Pharmaceuticals, Inc.|TARS - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Tarsus Pharmaceuticals Inc|TARS - Trailing Twelve Months Sales Growth
Fundamental company analysis:TARS - Tarsus Corp
Flagship merchandise of Tarsus Pharmaceuticals Inc

For Tarsus Pharmaceuticals (TARS), which integrates AI into the development of ophthalmological drugs, this metric serves as an indicator of the efficiency of innovation capitalization. By analyzing the 12-month net income per share chart, an investor assesses the final earnings distributed per share, allowing them to filter out market noise and understand the extent to which the automation of drop synthesis converts into real shareholder value.

Main competitors

SMMT - Earnings per share for the last twelve months|MRNA (Moderna) - Earnings per share for the last 12 months|PCVX: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months CRMD (CorMedix Corp)|MCRB (Seres Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Spero Therapeutics SPRO|Net earnings per share (EPS TTM) SCYX|Net earnings per share for the last 12 months AN2 Bio ANTX|PolyPid - Net earnings per share for the last 12 months|Net earnings per share for the last four quarters YS Biopharma Co., Ltd. (LSB)|Iterum Therapeutics PLC - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BiomX PHGE|soligenix.com (SNGX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months 60 Degrees Pharma (SXTP)|Earnings per share for the last twelve months Oragenics|Earnings per share for the last 12 months OPGN (OpGen Corporation)